Skip to main
JNJ

JNJ Stock Forecast & Price Target

JNJ Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 33%
Buy 28%
Hold 39%
Sell 0%
Strong Sell 0%

Bulls say

Johnson & Johnson has demonstrated robust operational sales growth of 11.5% in 4Q 2025, excluding the impact from generic competition affecting Stelara, indicating a strong performance in its innovative medicine division. The company’s revenue estimate for 2026 has been raised to $100.42 billion, benefiting from significant contributions from products like Tremfya, Rybrevant, and Tecvayli, reflecting positive trends in key therapeutic areas. Additionally, the stock has shown impressive performance, increasing approximately 30% since July 1, enhancing investor confidence amidst ongoing positive earnings revisions and favorable product dynamics.

Bears say

Johnson & Johnson's stock outlook is negatively impacted by the impending loss of patent exclusivity for key products, which historically leads to rapid sales declines due to competition from generics and biosimilars. Additionally, the company faces significant risks related to the disappointing launch of new products and critical pipeline data readouts, alongside macroeconomic concerns such as U.S. drug pricing reform and litigation risks from ongoing product-liability lawsuits. The recently unfavorable Daubert ruling further introduces uncertainty regarding the company's legal exposure, potentially affecting investor confidence and contributing to volatility in JNJ shares.

JNJ has been analyzed by 18 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 28% recommend Buy, 39% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Johnson & Johnson (JNJ) Forecast

Analysts have given JNJ a Buy based on their latest research and market trends.

According to 18 analysts, JNJ has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $235.28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $235.28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Johnson & Johnson (JNJ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.